精神病の家族歴を持つ個人のカンナビノイドシステムを調査する
The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.
調査の概要
研究の種類
入学 (実際)
段階
- 初期フェーズ 1
連絡先と場所
研究場所
-
-
Connecticut
-
West Haven、Connecticut、アメリカ、06516
- VA Connecticut Healthcare System
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria FHP:
- Exposure to cannabis at least once in their lifetime
- Medically and psychiatrically healthy based on screening
- Having one relative with a confirmed psychotic disorder
Exclusion Criteria FHP:
- Current or lifetime major DSM-IV Axis I disorder
- Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
- Major or unstable medical illness that might impact safety of the subject in the study
- Cannabis naive
- IQ less than 85
- Less than a high school diploma or its educational equivalent
- Pregnancy or lactation
- Major current or recent (<6 weeks) psychosocial stressors.
Inclusion Criteria FHN :
- Exposure to cannabis at least once in their lifetime
- Medically and psychiatrically healthy based on screening
Exclusion Criteria FHN:
- Having a family member with psychosis
- Current or lifetime major DSM-IV Axis I disorder
- Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
- Major or unstable medical illness that might impact safety of the subject in the study
- Cannabis naive
- IQ less than 85
- Less than a high school diploma or its educational equivalent
- Pregnancy or lactation
- Major current or recent (<6 weeks) psychosocial stressors.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:No Family History of Psychosis (FHN)
Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions. |
placebo Subjects will receive 0.010mg/kg.
他の名前:
Subjects will receive 0.018 mg/kg over 20 minutes.
他の名前:
|
|
実験的:Family History of Psychosis (FHP)
Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions. |
placebo Subjects will receive 0.010mg/kg.
他の名前:
Subjects will receive 0.018 mg/kg over 20 minutes.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
時間枠:-30 min from administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
-30 min from administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
時間枠:+80 min from administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+80 min from administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
時間枠:+150 min of administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+150 min of administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
時間枠:+240 min of administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+240 min of administration of THC
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinician Administered Dissociative Symptoms Scale (CADSS)
時間枠:-30 min, +15 min, +80 min, +150 min, +240 min
|
Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment. |
-30 min, +15 min, +80 min, +150 min, +240 min
|
|
Visual Analog Scale (VAS)
時間枠:-30 min, +15 min, +80 min, +150 min, +240 min
|
Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high", "anxious", "calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects. |
-30 min, +15 min, +80 min, +150 min, +240 min
|
|
Hopkins Verbal Learning Test (HVLT)
時間枠:+50 min
|
The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects. |
+50 min
|
|
Psychotomimetic States Inventory (PSI)
時間枠:-30 min, +240 min
|
The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC. |
-30 min, +240 min
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Mohini Ranganathan, MD、Yale University
研究記録日
主要日程の研究
研究開始
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。